Literature DB >> 2649753

Biased selection and regression toward the mean in three Medicare HMO demonstrations: a survival analysis of enrollees and disenrollees.

G Riley1, E Rabey, J Kasper.   

Abstract

Mortality of aged Medicare enrollees in three demonstration health maintenance organizations (HMOs) was compared with that of three cohorts of local fee-for-service (FFS) beneficiaries as a measure of group differences in health status. Mortality of the HMO and FFS cohorts was tracked via life-table analysis for 6 years after enrollment to measure the persistence of health status differences existing at enrollment. After adjustment for age, sex, Medicaid-eligibility, and institutional status, HMO enrollee mortality was lower than FFS at all three plans in the first year after enrollment. Enrollee mortality at two plans increased to near FFS levels in year 2 and remained relatively stable thereafter. Enrollee mortality at the third plan increased toward FFS levels more gradually and was significantly below FFS levels for the first 5 years of follow-up. Mortality of disenrollees in the 2 years after disenrollment was significantly higher than that of the continuously enrolled in one plan and marginally significantly higher in a second. These findings suggest a pattern of favorable selection at enrollment, followed by different rates of decay in the favorable health status of enrollees. Other health status measures may exhibit different patterns, however. Selection effects may cause payments based on Medicare's AAPCC to be too high or low, in some cases for several years after enrollment.

Mesh:

Year:  1989        PMID: 2649753     DOI: 10.1097/00005650-198904000-00002

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  14 in total

1.  Comparing mortality and time until death for medicare HMO and FFS beneficiaries.

Authors:  M L Maciejewski; B Dowd; K T Call; R Feldman
Journal:  Health Serv Res       Date:  2001-02       Impact factor: 3.402

2.  Understanding biased selection in Medicare HMOs.

Authors:  Michelle M Mello; Sally C Stearns; Edward C Norton; Thomas C Ricketts
Journal:  Health Serv Res       Date:  2003-06       Impact factor: 3.402

3.  Enrollee health status under Medicare risk contracts: an analysis of mortality rates.

Authors:  G Riley; J Lubitz; E Rabey
Journal:  Health Serv Res       Date:  1991-06       Impact factor: 3.402

4.  MEDICAL EXPENDITURE RISK AND HOUSEHOLD PORTFOLIO CHOICE.

Authors:  Dana Goldman; Nicole Maestas
Journal:  J Appl Econ (Chichester Engl)       Date:  2013-06-01

5.  Adjusted Mortality Rates Are Lower For Medicare Advantage Than Traditional Medicare, But The Rates Converge Over Time.

Authors:  Joseph P Newhouse; Mary Price; J Michael McWilliams; John Hsu; Jeffrey Souza; Bruce E Landon
Journal:  Health Aff (Millwood)       Date:  2019-04       Impact factor: 6.301

6.  Disenrollment from Medicare managed care among beneficiaries with and without a cancer diagnosis.

Authors:  Elena B Elkin; Nicole Ishill; Gerald F Riley; Peter B Bach; Mithat Gonen; Colin B Begg; Deborah Schrag
Journal:  J Natl Cancer Inst       Date:  2008-07-08       Impact factor: 13.506

7.  Health care expenditures after introduction of a gatekeeper and a global budget in a Swiss health insurance plan.

Authors:  J F Etter; T V Perneger
Journal:  J Epidemiol Community Health       Date:  1998-06       Impact factor: 3.710

8.  Social/health maintenance organization and fee-for-service health outcomes over time.

Authors:  K G Manton; R Newcomer; G R Lowrimore; J C Vertrees; C Harrington
Journal:  Health Care Financ Rev       Date:  1993

9.  Trends in the health status of medicare risk contract enrollees.

Authors:  Gerald Riley; Carlos Zarabozo
Journal:  Health Care Financ Rev       Date:  2006

10.  Patient selection in the ESRD managed care demonstration.

Authors:  Jennifer R Shapiro; Dawn M Dykstra; Ron Pisoni; Nancy Beronja; Daniel S Gaylin; Caitlin Carroll Oppenheimer; Robert J Rubin; Philip J Held
Journal:  Health Care Financ Rev       Date:  2003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.